We spoke with Dr. Monika Joshi on the use of radiation therapy and durvalumab in patients with locally advanced bladder cancer.
We spoke with Dr. Mikkael Sekeres on the difficulty of cancer patients meeting eligibility criteria for clinical trials.
We are speaking with Sonali Smith, MD, an associate professor of medicine and the director of the lymphoma program at the University of Chicago. At the ASH meeting, Dr. Smith will give a talk called “Emerging Biology Leading to New Therapies in Follicular Lymphoma.”
In this interview, Dr. Ivan Borrello talks about a new approach to treating multiple myeloma at the American Society of Hematology Annual Meeting, held December 3–6, 2016.
As part of our coverage of the ASH Annual Meeting held December 3rd to 6th in San Diego, today we are speaking with Kim Nichols, MD, director of the Cancer Predisposition Division at St. Jude Children's Research Hospital. At this year’s meeting, Dr. Nichols will be participating in a session on genetic susceptibility to leukemia.
Today, we are speaking with Dr. Alexander Drilon, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City who specializes in treating patients with lung cancer. Dr. Drilon recently spoke at the New York Lung Cancer Symposium held on November 12th on three relatively new molecular drug targets for lung cancer.
Professor Mishra and his colleagues recently developed a program called Pipeline for Cancer Inference or PiCnIc for short that analyzes patient tumor sequencing data to create potential ways that the tumor may evolve and progress that is patient-personalized.
Dr. Amitkumar Mehta talks about the various effects of daratumumab on multiple myeloma cells.
As part of our coverage of the annual ASCO conference, we spoke with Dr. Veronika Bachanova on the role of NK cell therapy in hematologic malignancies.
In this interview, we speak with Dr. Robert Ferris about the results from the CheckMate-141 study, which investigated the efficacy of nivolumab in head and neck cancer.